Deutsche Beteiligungs AG (DBAG) has published an update on its portfolio and investment activities in the wake of the coronavirus outbreak, including the fact that the NAV of its private equity investments has fallen by around 20%.
Also backing the biotech startup were the Zürcher Kantonalbank and Greencross Medical Science Corp
Company plans to use the fresh capital to further expand, develop new features and scale up its team
EVentures, 468 Capital and HV Holtzbrinck back the round for the climate change mitigation app
Clessidra has been in negotiations for the acquisition of the Italian wine producer since February 2020